Health and Healthcare
Biotechs and Related Hitting 52-Week Lows Too (BBH, AMGN, AMLN, ARNA, GERN, INGN, PGNX, SUPG)
Published:
Last Updated:
Today has been a rough day with more 52-week lows than we can recall in quite some time. The biotechs haven’t been immune. You can even see that the Biotech HOLDRs (BBH) at $160+ are only about 2% above the 52-week lows of $157.95, while the iShares Nasdaq Biotechnology (IBB) ETF at $80.29 is only about half-way in its 52-week trading range of $72.37 to $89.00. The difference is because of the composition.
Here are BIOTECH STOCKS hitting 52-week lows today:
- Amgen (AMGN)
- Amylin Pharma (AMLN)
- Arena Pharma (ARNA)
- Cleveland Biolabs (CBLI)
- Geron (GERN)
- Introgen (INGN)
- Progenics Pharma (PGNX)
- Somaxon Pharma (SOMX)
- Spectrum Pharma (SPPI)
- Supergen (SUPG)
If you wantto see how bad today is look at the master list of 52-week lows we compiled two hours ago with financials, restaurants, retail, REIT, property, tech and more. It’s a huge list.
Jon C. Ogg
January 4, 2008
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
